Post-Exposure Prophylaxis Guidelines

Introduction

Post-exposure prophylaxis (PEP) is a crucial aspect of preventing sexually transmitted infections (STIs) and other diseases, with doxycycline being a recommended antibiotic for PEP, as supported by the Centers for Disease Control and Prevention (CDC) and the American Thoracic Society 1, 2

The CDC recommends doxycycline PEP as a single 200mg dose after each sexual encounter, with a maximum of one 200mg dose per 24-hour period, taken within 72 hours of exposure 1
Standard dosing is 200mg doxycycline taken as soon as possible after condomless sex, but within 72 hours of exposure, with patients instructed to take the medication with food and a full glass of water (8 oz) while remaining upright for at least one hour after taking the medication to prevent esophageal irritation and maximize absorption, as recommended by the CDC and the American Thoracic Society 1, 2
Patients should avoid dairy products, antacids, and supplements with calcium, iron, or magnesium for 2-3 hours before or after the dose, as recommended by the American Thoracic Society and the CDC 2, 1

The CDC specifically recommends doxycycline PEP for men who have sex with men, transgender women, and particularly those with a history of bacterial STIs in the past year, as part of a comprehensive sexual health approach including other prevention strategies 1

Each 200mg dose provides protection for encounters within the previous 72 hours, with individuals recommended to return for STI screening every 3-6 months and undergo HIV screening per CDC guidelines 1
Patients on doxycycline PEP should undergo STI screening at anatomic sites of exposure every 3-6 months, HIV screening according to current CDC guidelines, assessment of side effects from doxycycline, and re-evaluation of continued need for doxy PEP every 3-6 months, as recommended by the CDC 1

Doxycycline PEP has demonstrated significant reductions in Chlamydia (70-88% reduction) and Syphilis (73-87% reduction), although effects on gonorrhea are less consistent due to resistance patterns, as reported by the CDC and JAMA 1, 3
There is a potential for antimicrobial resistance development with prolonged use, with increased tetracycline-resistant S. aureus with extended doxycycline use, as warned by the CDC 1
The development of antimicrobial resistance is a significant concern with widespread doxycycline PEP use, and the decision to use doxycycline PEP should balance short-term clinical benefits against this risk, as noted by the CDC and the Infectious Diseases Society of America 1, 4

Doxycycline is contraindicated in patients with hypersensitivity to doxycycline or tetracyclines, children under 12 years, and during pregnancy and lactation due to potential for permanent teeth discoloration and bone growth inhibition, as recommended by the American Academy of Dermatology and the American Thoracic Society 2, 5
Pregnancy and lactation are contraindications due to potential risks to the fetus or nursing infant, as recommended by the American Academy of Dermatology 5
Doxycycline should be avoided in children under 8 years due to dental staining and bone growth effects, as implied by the American Academy of Dermatology 5

Doxycycline may be used for tick bite prophylaxis in specific circumstances, such as when the tick is identified as Ixodes scapularis, attached for ≥36 hours, and treatment is initiated within 72 hours of tick removal, with a local infection rate of ≥20% and no contraindications, as recommended by the Infectious Diseases Society of America 4

Regular assessment for efficacy and side effects is necessary every 1-3 months, and monitoring for development of resistance, especially with long-term use, is crucial, as recommended by the American Academy of Dermatology and the CDC 5, 1